Terms: = Prostate cancer AND KLK2, P20151, 3817, ENSG00000167751, MGC12201, hK2, KLK2A2 AND Prognosis
27 results:
1. Construction of Glycolytic Regulator Gene Signature to Predict the prognosis and Tumor Immune Cell Infiltration Levels for prostate cancer.
Zhang L; Wang B; Wang ZS; Guo YL; Shen H
Comput Math Methods Med; 2022; 2022():9273559. PubMed ID: 35242214
[TBL] [Abstract] [Full Text] [Related]
2. Reduced klk2 expression is a strong and independent predictor of poor prognosis in ERG-negative prostate cancer.
Bonk S; Kluth M; Jansen K; Hube-Magg C; Makrypidi-Fraune G; Höflmayer D; Weidemann S; Möller K; Uhlig R; Büscheck F; Luebke AM; Burandt E; Clauditz TS; Steurer S; Schlomm T; Huland H; Heinzer H; Sauter G; Simon R; Dum D
Prostate; 2020 Sep; 80(13):1097-1107. PubMed ID: 32628300
[TBL] [Abstract] [Full Text] [Related]
3. Glycolysis inhibition and apoptosis induction in human prostate cancer cells by FV-429-mediated regulation of AR-AKT-hk2 signaling network.
Chen X; Wei L; Yang L; Guo W; Guo Q; Zhou Y
Food Chem Toxicol; 2020 Sep; 143():111517. PubMed ID: 32619556
[TBL] [Abstract] [Full Text] [Related]
4. New challenges in integrated diagnosis by imaging and osteo-immunology in bone lesions.
Schiano C; Soricelli A; De Nigris F; Napoli C
Expert Rev Clin Immunol; 2019 Mar; 15(3):289-301. PubMed ID: 30570412
[TBL] [Abstract] [Full Text] [Related]
5. Downregulation of miR‑224‑5p in prostate cancer and its relevant molecular mechanism via TCGA, GEO database and in silico analyses.
Gan BL; Zhang LJ; Gao L; Ma FC; He RQ; Chen G; Ma J; Zhong JC; Hu XH
Oncol Rep; 2018 Dec; 40(6):3171-3188. PubMed ID: 30542718
[TBL] [Abstract] [Full Text] [Related]
6. Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer.
Chen J; Cao S; Situ B; Zhong J; Hu Y; Li S; Huang J; Xu J; Wu S; Lin J; Zhao Q; Cai Z; Zheng L; Wang Q
J Exp Clin Cancer Res; 2018 Jun; 37(1):127. PubMed ID: 29954422
[TBL] [Abstract] [Full Text] [Related]
7. Expression of HMGB2 indicates worse survival of patients and is required for the maintenance of Warburg effect in pancreatic cancer.
Cai X; Ding H; Liu Y; Pan G; Li Q; Yang Z; Liu W
Acta Biochim Biophys Sin (Shanghai); 2017 Feb; 49(2):119-127. PubMed ID: 28069585
[TBL] [Abstract] [Full Text] [Related]
8. A 2-Gene Panel Derived From prostate cancer-Enhanced Transcripts in Whole Blood Is Prognostic for Survival and Predicts Treatment Benefit in Metastatic Castration-Resistant prostate cancer.
Heck MM; Thalgott M; Schmid SC; Oh WK; Gong Y; Wang L; Zhu J; Seitz AK; Porst D; Höppner M; Retz M; Gschwend JE; Nawroth R
Prostate; 2016 Sep; 76(13):1160-8. PubMed ID: 27198487
[TBL] [Abstract] [Full Text] [Related]
9. Loss of miR-378 in prostate cancer, a common regulator of klk2 and KLK4, correlates with aggressive disease phenotype and predicts the short-term relapse of the patients.
Avgeris M; Stravodimos K; Scorilas A
Biol Chem; 2014 Sep; 395(9):1095-104. PubMed ID: 25153390
[TBL] [Abstract] [Full Text] [Related]
10. Kallikrein-related peptidases in cancers of gastrointestinal tract: an inside view of their role and clinical significance.
Linardoutsos D; Gazouli M; Machairas A; Bramis I; Zografos GC
J BUON; 2014; 19(1):53-9. PubMed ID: 24659643
[TBL] [Abstract] [Full Text] [Related]
11. Analysis of fusion gene expression in prostate tumors by using single-end reads.
Xie DD; Li JY; Wang Y; Chen L; Yu DX
Genet Mol Res; 2013 Aug; 12(3):2886-94. PubMed ID: 24065644
[TBL] [Abstract] [Full Text] [Related]
12. Exploratory study of a klk2 polymorphism as a prognostic marker in prostate cancer.
Kohli M; Rothberg PG; Feng C; Messing E; Joseph J; Rao SS; Hendershot A; Sahsrabudhe D
Cancer Biomark; 2010; 7(2):101-8. PubMed ID: 21178268
[TBL] [Abstract] [Full Text] [Related]
13. Kallikrein-related peptidase genes as promising biomarkers for prognosis and monitoring of human malignancies.
Avgeris M; Mavridis K; Scorilas A
Biol Chem; 2010 May; 391(5):505-11. PubMed ID: 20302518
[TBL] [Abstract] [Full Text] [Related]
14. prostate kallikrein markers in diagnosis, risk stratification and prognosis.
Ulmert D; O'Brien MF; Bjartell AS; Lilja H
Nat Rev Urol; 2009 Jul; 6(7):384-91. PubMed ID: 19578355
[TBL] [Abstract] [Full Text] [Related]
15. Screening for prostate cancer: an update.
Shariat SF; Scardino PT; Lilja H
Can J Urol; 2008 Dec; 15(6):4363-74. PubMed ID: 19046489
[TBL] [Abstract] [Full Text] [Related]
16. Real-time quantitative RT-PCR assessment of PIM-1 and hk2 mRNA expression in benign prostate hyperplasia and prostate cancer.
He HC; Bi XC; Zheng ZW; Dai QS; Han ZD; Liang YX; Ye YK; Zeng GH; Zhu G; Zhong WD
Med Oncol; 2009; 26(3):303-8. PubMed ID: 19003546
[TBL] [Abstract] [Full Text] [Related]
17. Emerging biomarkers for the diagnosis and prognosis of prostate cancer.
Sardana G; Dowell B; Diamandis EP
Clin Chem; 2008 Dec; 54(12):1951-60. PubMed ID: 18927246
[TBL] [Abstract] [Full Text] [Related]
18. Biomarkers associated with breast cancer are associated with obesity.
Sauter ER; Scott S; Hewett J; Kliethermes B; Ruhlen RL; Basarakodu K; de la Torre R
Cancer Detect Prev; 2008; 32(2):149-55. PubMed ID: 18639389
[TBL] [Abstract] [Full Text] [Related]
19. Human tissue kallikreins: the cancer biomarker family.
Paliouras M; Borgono C; Diamandis EP
Cancer Lett; 2007 Apr; 249(1):61-79. PubMed ID: 17275179
[TBL] [Abstract] [Full Text] [Related]
20. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Steuber T; Vickers AJ; Serio AM; Vaisanen V; Haese A; Pettersson K; Eastham JA; Scardino PT; Huland H; Lilja H
Clin Chem; 2007 Feb; 53(2):233-40. PubMed ID: 17185368
[TBL] [Abstract] [Full Text] [Related]
[Next]
